Bayesian Capital Management’s Gilead Sciences GILD Stock Holding History

Bayesian Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	9,100 +6,933	+320%	+$913K	0.74%	34
2026 Q1	$302K	Buy	+2,167	New	+$303K	0.37%	87
2025 Q4	–	Sell	-19,036	Closed	-$2.11M	–	292
2025 Q3	$2.11M	Buy	+19,036	New	+$2.16M	0.43%	65
2025 Q2	–	Sell	-51,100	Closed	-$5.73M	–	670
2025 Q1	$5.73M	Buy	51,100 +29,500	+137%	+$3.04M	0.95%	11
2024 Q4	$2M	Buy	+21,600	New	+$1.94M	0.24%	125
2024 Q2	–	Sell	-16,200	Closed	-$1.19M	–	883
2024 Q1	$1.19M	Buy	+16,200	New	+$1.25M	0.11%	255
2023 Q4	–	Sell	-61,100	Closed	-$4.58M	–	856
2023 Q3	$4.58M	Buy	+61,100	New	+$4.7M	0.52%	41
2023 Q2	–	Sell	-28,300	Closed	-$2.35M	–	892
2023 Q1	$2.35M	Buy	+28,300	New	+$2.34M	0.29%	95
2022 Q4	–	Sell	-9,400	Closed	-$580K	–	860
2022 Q3	$580K	Buy	+9,400	New	+$593K	0.12%	244
2021 Q4	–	Sell	-35,400	Closed	-$2.47M	–	434
2021 Q3	$2.47M	Buy	+35,400	New	+$2.49M	0.72%	19
2021 Q1	–	Sell	-54,100	Closed	-$3.15M	–	594
2020 Q4	$3.15M	Buy	54,100 +26,700	+97%	+$1.61M	0.82%	17
2020 Q3	$1.73M	Buy	+27,400	New	+$1.9M	0.42%	54
2019 Q4	–	Sell	-12,689	Closed	-$804K	–	659
2019 Q3	$804K	Buy	+12,689	New	+$829K	0.15%	189
2017 Q4	–	Sell	-15,300	Closed	-$1.24M	–	608
2017 Q3	$1.24M	Buy	+15,300	New	+$1.17M	0.3%	101
2016 Q2	–	Sell	-3,168	Closed	-$291K	–	448
2016 Q1	$291K	Buy	+3,168	New	+$286K	0.27%	159

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayesian Capital Management's GILD Position: Q2 2026 in Review

Bayesian Capital Management increased its Gilead Sciences (GILD) stake by 320% in Q2 2026, buying an estimated $913K and bringing the position to 9,100 shares worth $1.15M. The position accounts for 0.74% of the portfolio, ranked #34.

Bayesian Capital Management first reported a position in GILD in Q1 2016 and has held it in 15 quarters since. The position peaked at $5.73M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Bayesian Capital Management held 9,100 shares of Gilead Sciences worth $1.15M as of Q2 2026.
Bayesian Capital Management bought 6,933 Gilead Sciences shares in Q2 2026, an estimated $913K.
Gilead Sciences made up 0.74% of Bayesian Capital Management's portfolio in Q2 2026, its #34 holding.
Bayesian Capital Management first reported a position in Gilead Sciences in Q1 2016 and has held it in 15 quarters since.
Bayesian Capital Management's Gilead Sciences position peaked at $5.73M in Q1 2025.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.